Comparing Biofrontera (NASDAQ:BFRI) & Sandoz Group (OTCMKTS:SDZNY)

Biofrontera (NASDAQ:BFRI) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Biofrontera and Sandoz Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	0	0	1	0	3.00
Sandoz Group	0	0	3	0	3.00

Biofrontera currently has a consensus price target of $18.00, suggesting a potential upside of 432.54%. Given Biofrontera’s higher possible upside, equities research analysts plainly believe Biofrontera is more favorable than Sandoz Group.

Insider and Institutional Ownership

58.4% of Biofrontera shares are owned by institutional investors. 0.6% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Biofrontera and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biofrontera	-78.65%	-192.05%	-57.24%
Sandoz Group	N/A	N/A	N/A

Valuation & Earnings

This table compares Biofrontera and Sandoz Group’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$33.62 million	0.15	-$640,000.00	($20.27)	-0.17
Sandoz Group	N/A	N/A	N/A	N/A	N/A

Sandoz Group has lower revenue, but higher earnings than Biofrontera.

About Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.